AMSTERDAM, July 7, 2011 /PRNewswire/ --
Amsterdam Molecular Therapeutics (Euronext: AMT), a leader in
the field of human gene therapy, announced today that it has filed
a request for re-examination of the Marketing Authorisation
Application for Glybera® with the European Medicines Agency.
Glybera is a gene therapy for the genetic disorder lipoprotein
lipase deficiency. The Company expects that the re-examination of
the dossier will be completed by the end of 2011.
AMT is a world leader in the development of human gene
based therapies. The company's lead product Glybera®, a gene
therapy for lipoprotein lipase deficiency (LPLD), is currently
under review by the European Medicines Agency (EMA). If approved,
Glybera will be the first gene therapy product to be marketed in
Europe. AMT also has a product pipeline of several gene therapy
products in development for hemophilia B, Duchenne muscular
dystrophy, acute intermittent porphyria, Parkinson's disease and
SanfilippoB. Using adeno-associated viral (AAV) derived vectors as
the delivery vehicle of choice for therapeutic genes, the company
has been able to design and validate probably the world's first
stable and scalable AAV manufacturing platform. This
proprietary platform can be applied to a large number of
rare (orphan) diseases caused by one faulty gene and allows
AMT to pursue its strategy of focusing on this sector of the
industry. AMT was founded in 1998 and is based in Amsterdam.
Further information can be found at http://www.amtbiopharma.com.
Certain statements in this press release are"forward-looking statements"including
those that refer to management's plans and
expectations for future operations, prospects and financial
condition. Words such as"strategy,""expects,""
"and other words of similar meaning are intended to
identify such forward-looking statements. Such statements are based
on the current expectations of the management of AMT only. Undue
reliance should not be placed on these statements because, by their
nature, they are subject to known and unknown risks and can be
affected by factors that are beyond the control of AMT. Actual
results could differ materially from current expectations due to a
number of factors and uncertainties affecting AMT's
business. AMT expressly disclaims any intent or obligation to
update any forward-looking statements herein except as required by
SOURCE Amsterdam Molecular Therapeutics B.V